ProMIS expects to report six-month interim results from PRECISE-AD in the first half of 2026, with topline results ...

经过十余年迭代优化，科学家最终将靶点锁定在Aβ聚集级联反应中最具毒性的可溶性寡聚体阶段。新一代抗体药物终于突破瓶颈——2023年完全获批的仑卡奈单抗（Lecanemab）标志着精准医疗的重大突破。

Notably, microglia spatially associated with amyloid plaques exhibited increased expression of TREM2 and ApoE compared to ...

Bristol-Myers Squibb (NYSE:BMY) recently announced positive topline results from its Phase 3 trials for Sotyktu, generating ...

Aβ的“前身”是正常存在于神经元中的淀粉样前体蛋白（APP），在某些情况下被蛋白酶错误切割而产生。在AD患者的大脑中，Aβ的生成源源不断地 ...

The antibodies recognizing multiple nucleoporins (RL1 and Mab414 ... There is also no clear hypothesis on how Aβ pathology may affect nucleoporin levels and NPC function. All functional NCT ...

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer ...

Even with significant expansion in the global market for antibodies used in clinical care and research, scientists recognize that there is still untapped potential for finding new antibodies.